Utilizing the AACR GENIE BPC NSCLC 2.0-public dataset, we demonstrated that KRAS/SMARCA4 class 1 co-mutations were significantly associated with worse overall survival compared to KRAS mutations alone in NSCLC patients. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.